Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19008979 | 0.92 | MEN1 (0.46) | ACHEMEN1KMT2ANPC1RAB9A | |
| SCHEMBL13456606 | 0.78 | POLB (0.44) | ACHEALDH1A1SIGMAR1KCNH2 | |
| SCHEMBL23468026 | 0.75 | ALDH1A1 (0.47) | ACHEMEN1KMT2ANPC1RAB9A | |
| SCHEMBL10308261 | 0.73 | NPC1 (0.33) | NPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL4547889 | 0.72 | SIGMAR1 (0.59) | ACHEMEN1KMT2ANPC1RAB9A | |
| SCHEMBL16417106 | 0.72 | ALDH1A1 (0.47) | KMT2AALDH1A1KCNH2 | |
| SCHEMBL19335631 | 0.71 | POLB (0.48) | ALDH1A1SMN1; SMN2SIGMAR1KCNH2 | |
| SCHEMBL12090079 | 0.71 | KDM5B (0.47) | ACHEMEN1KMT2ANPC1RAB9A | |
| SCHEMBL7769654 | 0.70 | ATM (0.46) | ACHEMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL21479290 | 0.70 | SIGMAR1 (0.64) | MEN1KMT2ANPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | MTOR, RICTOR, PIK3CA | ACHE 4843/4885MEN1 2648/4885KMT2A 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.